A panel of advisers to the Food and Drug Administration has recommended approval of a new drug for Type 2 diabetes that works in a new way.
The panel also raised concerns about possible side effects. According to The New York Times, the medicine, canagliflozin, is from Johnson & Johnson and it lowers blood sugar by causing it to be excreted in urine. Patients may also lose weight. But studies suggest the drug also may temporarily increase risks for stroke and heart attack in some patients.